Showing results (201-210 of 220) with videos related to
Sort By:
Pageof 22
Expert Opinion on Investigational Drugs|October 2, 2003
Treatment of dementia with neurotransmission modulationSheila A Doggrell, Suzanne EvansExpert Opinion on Pharmacotherapy|January 1, 2014
Canagliflozin - something new for type 2 diabetes, but is it safe and efficacious?Sheila A Doggrell, Kerry McIntyreExpert Opinion on Pharmacotherapy|July 8, 2014
Dapagliflozin--do we need it registered for type 2 diabetes?Sheila A Doggrell, Rinku TuliInternational Journal of Clinical Pharmacy|April 9, 2014
The association between the measurement of adherence to anti-diabetes medicine and the HbA1cSheila A Doggrell, Servane WarotExpert Opinion on Investigational Drugs|November 26, 2010
Perspective: does ranolazine have potential for the treatment of atrial fibrillation?Jules C Hancox, Sheila A DoggrellExpert Opinion on Pharmacotherapy|March 20, 2012
PALLAS: limiting indications for dronedarone treatment of atrial fibrillation?Sheila A Doggrell, Jules C HancoxExpert Opinion on Investigational Drugs|July 2, 2003
Is timing everything? Therapeutic potential of modulators of cardiac Na(+) transportersSheila A Doggrell, Jules C HancoxExpert Opinion on Investigational Drugs|April 23, 2004
Dronedarone: an amiodarone analogueSheila A Doggrell, Jules C HancoxExpert Opinion on Investigational Drugs|June 2, 2005
Ibutilide--recent molecular insights and accumulating evidence for use in atrial flutter and fibrillationSheila A Doggrell, Jules C HancoxExpert Opinion on Drug Safety|April 13, 2013
Cardiac safety concerns for ondansetron, an antiemetic commonly used for nausea linked to cancer treatment and following anaesthesiaSheila A Doggrell, Jules C HancoxPageof 22